Current Management of Patients Taking Immunosuppressive Medication and Targeted Therapies: National Survey Within Oral Surgery and Oral and Maxillofacial Surgery

ABSTRACT Introduction Systemic immunosuppressive medication and targeted therapies (IMTT) can increase the risk of surgical procedures to patients. The risks of continuing their systemic IMTT medication during the pre‐, peri‐ and post‐operative period must be weighed up against the risk of stopping their medication. Currently, there is a paucity of evidence and national guidance on the management of oral surgery and oral and maxillofacial surgery patients taking IMTT. Materials and Methods A cross‐sectional online survey was distributed to clinicians within primary and secondary care who were providing oral surgery or oral and maxillofacial surgery services. Distribution was through the British Association of Oral Surgery (BAOS) and the British Association of Oral and Maxillofacial Surgery (BAOMS). The survey explored current practice and available guidance with regard to alteration of IMTT dosing intervals and contact with the prescribing clinician. Results One hundred and forty‐six surveys were completed by clinicians working in oral surgery or maxillofacial surgery settings, and general dental practitioners with a special interest in oral surgery. The majority of responses were collected from clinicians practising in the UK both in primary and secondary care. The results show that clinicians frequently treat patients taking IMTT. Currently, there are a variety of approaches to managing patients on IMTT and a lack of standardisation across the specialities. Conclusion Further research and evidence‐based national guidance, specifically for oral surgery and oral and maxillofacial surgery, would provide clarity on the optimal care for those taking IMTT.